Allogene Therapeutics Inc. closed a common stock offering, raising about $632.5 million.

The South San Francisco, Calif.-based biotechnology company sold a total of 13,457,447 common shares at $47 apiece, including 1,755,319 shares sold as part of the underwriters' full exercise of their overallotment option.

Goldman Sachs & Co. LLC, Jefferies LLC, and Cowen and Co. LLC served as joint lead book-running managers, while Piper Sandler & Co. also served as book-running manager. Canaccord Genuity LLC, William Blair & Co. LLC and Oppenheimer & Co. Inc. were co-lead managers.